Coronavirus vaccine trials should be successful by end of 2020: AstraZeneca CEO

A health worker holds a COVID-19 sample collection kit of a vaccine trials' volunteer at the Wits RHI Shandukani Research Centre in Johannesburg. (Reuters)

AstraZeneca’s chief executive Pascal Soriot said on Thursday that it should know before the end of the year whether its experimental vaccine would protect people from COVID-19, if the British drugmaker is allowed to resume trials which were paused this week.

For more coronavirus news, visit our dedicated page.

It suspended the late-stage trials after an illness in a study subject in Britain. The patient was reportedly suffering from neurological symptoms associated with a rare spinal inflammatory disorder called transverse myelitis.

Soriot said during a call on the vaccine, which the World Health Organization (WHO) has flagged as the most promising in combatting coronavirus, that it was very common for a trial to be suspended, the difference being that the world was watching.

The CEO said AstraZeneca did not know the diagnosis for the volunteer in the trial, adding that it was not clear if they had transverse myelitis and more tests were needed.

Soriot said the diagnosis would be submitted to an independent safety committee and this would usually then tell the company whether trials can be resumed.

Read more:

Coronavirus: AstraZeneca puts COVID-19 vaccine trial on hold over safety concerns

Coronavirus may cause prolonged gut infection, scientists say

SHOW MORE
Last Update: Thursday, 10 September 2020 KSA 12:11 - GMT 09:11
Top